Randomized trial of text messaging (TM) to reduce early discontinuation of aromatase inhibitor (AI) therapy in women with breast cancer: SWOG S1105.

Dawn L. Hershman,Joseph M. Unger,Hillyer Grace,Anna Moseley,Kathryn B. Arnold,Shaker R. Dakhil,Benjamin Esparaz,Ming C. Kuan,Mark Graham,Douglas M. Lackowski,William Jeffery Edenfield,Zoneddy R. Dayao,Julie R. Gralow,Scott D. Ramsey,Alfred I. Neugut

Randomized trial of text messaging (TM) to reduce early discontinuation of aromatase inhibitor (AI) therapy in women with breast cancer: SWOG S1105.

2019

Dawn L. Hershman
Joseph M. Unger
Hillyer Grace
Anna Moseley
Kathryn B. Arnold
Shaker R. Dakhil
Benjamin Esparaz
Ming C. Kuan
Mark Graham
Douglas M. Lackowski
William Jeffery Edenfield
Zoneddy R. Dayao
Julie R. Gralow
Scott D. Ramsey
Alfred I. Neugut

6516Background: Non-adherence to AI’s for breast cancer is common and increases risk of recurrence. Text messaging (TM) has been shown to increase adherence to medications for chronic conditions. W...

Keywords:

Aromatase inhibitor
Oncology
Breast cancer
Randomized controlled trial
Physical therapy
Discontinuation
Internal medicine
Medicine
text messaging
early discontinuation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations